



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2013-002306-31/ Novartis Protocol ID CLCZ696A2320E1

*An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension*

Trial CLCZ696A2320E1 was cancelled with no patient enrollment and as such, no results will be reported.